10-Q Filing

ODYSIGHT.AI INC. CIK: 1577445 Q2 2021

Filing Information

Form Type	10-Q
Accession Number	`0001493152-21-019515`
Period End Date	20210630
Filing Date	20210812
Fiscal Year	2021
Fiscal Period	Q2
XBRL Instance	form10-q_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 70 Income Statement 44 Cash Flow Statement 116 Stockholders Equity 27

Balance Sheet 70 line items

Line Item	Tag	Value	Unit	Period
Common Stock, Par or Stated Value Per Share	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common Stock, Par or Stated Value Per Share	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common Stock, Shares Authorized	`CommonStockSharesAuthorized`	300.00M	shares	Point-in-time
Common Stock, Shares Authorized	`CommonStockSharesAuthorized`	75.00M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$21.77M	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	6.93M	shares	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	4.08M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$3.37M	USD	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	6.93M	shares	Point-in-time
Accounts receivable	`AccountsReceivableNetCurrent`	$60.00K	USD	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	4.08M	shares	Point-in-time
Accounts receivable	`AccountsReceivableNetCurrent`	$17.00K	USD	Point-in-time
Inventory	`InventoryGross`	$244.00K	USD	Point-in-time
Inventory	`InventoryGross`	$145.00K	USD	Point-in-time
Medigus receivable	`AccountsReceivableRelatedPartiesCurrent`	-	USD	Point-in-time
Medigus receivable	`AccountsReceivableRelatedPartiesCurrent`	$47.00K	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$348.00K	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$857.00K	USD	Point-in-time
Total current assets	`AssetsCurrent`	$4.03M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$22.84M	USD	Point-in-time
Contract fulfillment assets	`ContractWithCustomerAssetNetNoncurrent`	$1.51M	USD	Point-in-time
Contract fulfillment assets	`ContractWithCustomerAssetNetNoncurrent`	$1.13M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$400.00K	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$269.00K	USD	Point-in-time
Operating lease right-of-use assets	`OperatingLeaseRightOfUseAsset`	$385.00K	USD	Point-in-time
Operating lease right-of-use assets	`OperatingLeaseRightOfUseAsset`	$107.00K	USD	Point-in-time
Severance pay asset	`SeverancePayAsset`	$360.00K	USD	Point-in-time
Severance pay asset	`SeverancePayAsset`	$416.00K	USD	Point-in-time
Total non-current assets	`AssetsNoncurrent`	$2.71M	USD	Point-in-time
Total non-current assets	`AssetsNoncurrent`	$1.87M	USD	Point-in-time
TOTAL ASSETS	`Assets`	$25.55M	USD	Point-in-time
TOTAL ASSETS	`Assets`	$5.89M	USD	Point-in-time
Accounts payables	`AccountsPayableCurrent`	$79.00K	USD	Point-in-time
Accounts payables	`AccountsPayableCurrent`	$303.00K	USD	Point-in-time
Contract liabilities	`ContractWithCustomerLiabilityCurrent`	$69.00K	USD	Point-in-time
Contract liabilities	`ContractWithCustomerLiabilityCurrent`	-	USD	Point-in-time
Operating lease liabilities - short term	`OperatingLeaseLiabilityCurrent`	$187.00K	USD	Point-in-time
Operating lease liabilities - short term	`OperatingLeaseLiabilityCurrent`	$60.00K	USD	Point-in-time
Accrued compensation expenses	`EmployeeRelatedLiabilitiesCurrent`	$429.00K	USD	Point-in-time
Accrued compensation expenses	`EmployeeRelatedLiabilitiesCurrent`	$369.00K	USD	Point-in-time
Medigus payable	`AccountsPayableRelatedPartiesCurrent`	-	USD	Point-in-time
Medigus payable	`AccountsPayableRelatedPartiesCurrent`	$13.00K	USD	Point-in-time
Other accrued expenses	`OtherAccruedLiabilitiesCurrent`	$195.00K	USD	Point-in-time
Other accrued expenses	`OtherAccruedLiabilitiesCurrent`	$218.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$772.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$1.15M	USD	Point-in-time
Contract liabilities	`ContractWithCustomerLiabilityNoncurrent`	$779.00K	USD	Point-in-time
Contract liabilities	`ContractWithCustomerLiabilityNoncurrent`	$1.39M	USD	Point-in-time
Operating lease liabilities - long term	`OperatingLeaseLiabilityNoncurrent`	$198.00K	USD	Point-in-time
Operating lease liabilities - long term	`OperatingLeaseLiabilityNoncurrent`	$47.00K	USD	Point-in-time
Liability for severance pay	`LiabilityForSeverancePay`	$333.00K	USD	Point-in-time
Liability for severance pay	`LiabilityForSeverancePay`	$333.00K	USD	Point-in-time
Total non-current liabilities	`LiabilitiesNoncurrent`	$1.16M	USD	Point-in-time
Total non-current liabilities	`LiabilitiesNoncurrent`	$1.92M	USD	Point-in-time
TOTAL LIABILITIES	`Liabilities`	$3.07M	USD	Point-in-time
TOTAL LIABILITIES	`Liabilities`	$1.93M	USD	Point-in-time
Common stock, $0.001 par value; 300,000,000 and 75,000,000 shares authorized as of June 30, 2021 and December 31, 2020, 6,928,527 and 4,084,122 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively	`CommonStockValue`	$4.00K	USD	Point-in-time
Common stock, $0.001 par value; 300,000,000 and 75,000,000 shares authorized as of June 30, 2021 and December 31, 2020, 6,928,527 and 4,084,122 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively	`CommonStockValue`	$7.00K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapitalCommonStock`	$10.27M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapitalCommonStock`	$32.48M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-10.00M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-6.31M	USD	Point-in-time
TOTAL SHAREHOLDERS EQUITY	`StockholdersEquity`	$4.25M	USD	Point-in-time
TOTAL SHAREHOLDERS EQUITY	`StockholdersEquity`	$3.96M	USD	Point-in-time
TOTAL SHAREHOLDERS EQUITY	`StockholdersEquity`	$2.72M	USD	Point-in-time
TOTAL SHAREHOLDERS EQUITY	`StockholdersEquity`	$22.34M	USD	Point-in-time
TOTAL SHAREHOLDERS EQUITY	`StockholdersEquity`	$22.48M	USD	Point-in-time
TOTAL SHAREHOLDERS EQUITY	`StockholdersEquity`	$2.52M	USD	Point-in-time
TOTAL LIABILITIES AND SHAREHOLDERS EQUITY	`LiabilitiesAndStockholdersEquity`	$25.55M	USD	Point-in-time
TOTAL LIABILITIES AND SHAREHOLDERS EQUITY	`LiabilitiesAndStockholdersEquity`	$5.89M	USD	Point-in-time

Income Statement 44 line items

Line Item	Tag	Value	Unit	Period
Revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$34.00K	USD	1 Quarter
Revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$298.00K	USD	2 Qtrs
Revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$274.00K	USD	1 Quarter
Revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$74.00K	USD	2 Qtrs
Cost of revenues	`CostOfRevenue`	$407.00K	USD	1 Quarter
Cost of revenues	`CostOfRevenue`	$610.00K	USD	2 Qtrs
Cost of revenues	`CostOfRevenue`	$281.00K	USD	2 Qtrs
Cost of revenues	`CostOfRevenue`	$151.00K	USD	1 Quarter
Gross Loss	`GrossProfit`	$-133.00K	USD	1 Quarter
Gross Loss	`GrossProfit`	$-117.00K	USD	1 Quarter
Gross Loss	`GrossProfit`	$-207.00K	USD	2 Qtrs
Gross Loss	`GrossProfit`	$-312.00K	USD	2 Qtrs
Research and development expenses	`ResearchAndDevelopmentExpense`	$115.00K	USD	1 Quarter
Research and development expenses	`ResearchAndDevelopmentExpense`	$754.00K	USD	2 Qtrs
Research and development expenses	`ResearchAndDevelopmentExpense`	$370.00K	USD	2 Qtrs
Research and development expenses	`ResearchAndDevelopmentExpense`	$421.00K	USD	1 Quarter
Sales and marketing expenses	`SellingAndMarketingExpense`	$293.00K	USD	2 Qtrs
Sales and marketing expenses	`SellingAndMarketingExpense`	$188.00K	USD	2 Qtrs
Sales and marketing expenses	`SellingAndMarketingExpense`	$148.00K	USD	1 Quarter
Sales and marketing expenses	`SellingAndMarketingExpense`	$136.00K	USD	1 Quarter
General and administrative expenses	`GeneralAndAdministrativeExpense`	$1.40M	USD	1 Quarter
General and administrative expenses	`GeneralAndAdministrativeExpense`	$1.68M	USD	2 Qtrs
General and administrative expenses	`GeneralAndAdministrativeExpense`	$568.00K	USD	1 Quarter
General and administrative expenses	`GeneralAndAdministrativeExpense`	$2.33M	USD	2 Qtrs
Operating loss	`OperatingIncomeLoss`	$-2.10M	USD	1 Quarter
Operating loss	`OperatingIncomeLoss`	$-3.69M	USD	2 Qtrs
Operating loss	`OperatingIncomeLoss`	$-936.00K	USD	1 Quarter
Operating loss	`OperatingIncomeLoss`	$-2.44M	USD	2 Qtrs
Financing income (expenses), net	`FinancingIncomeExpensesNet`	$-34.00K	USD	1 Quarter
Financing income (expenses), net	`FinancingIncomeExpensesNet`	$62.00K	USD	2 Qtrs
Financing income (expenses), net	`FinancingIncomeExpensesNet`	$-7.00K	USD	2 Qtrs
Financing income (expenses), net	`FinancingIncomeExpensesNet`	$9.00K	USD	1 Quarter
Net Loss	`NetIncomeLoss`	$-2.38M	USD	2 Qtrs
Net Loss	`NetIncomeLoss`	$-970.00K	USD	1 Quarter
Net Loss	`NetIncomeLoss`	$-2.09M	USD	1 Quarter
Net Loss	`NetIncomeLoss`	$-3.69M	USD	2 Qtrs
Net loss per ordinary share (basic and diluted, USD)	`EarningsPerShareBasicAndDiluted`	$-0.67	USD	2 Qtrs
Net loss per ordinary share (basic and diluted, USD)	`EarningsPerShareBasicAndDiluted`	$-0.28	USD	1 Quarter
Net loss per ordinary share (basic and diluted, USD)	`EarningsPerShareBasicAndDiluted`	$-0.31	USD	1 Quarter
Net loss per ordinary share (basic and diluted, USD)	`EarningsPerShareBasicAndDiluted`	$-0.73	USD	2 Qtrs
Weighted average ordinary shares (basic and diluted, in thousands)	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	5.48M	shares	2 Qtrs
Weighted average ordinary shares (basic and diluted, in thousands)	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	3.24M	shares	2 Qtrs
Weighted average ordinary shares (basic and diluted, in thousands)	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	6.72M	shares	1 Quarter
Weighted average ordinary shares (basic and diluted, in thousands)	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	3.43M	shares	1 Quarter

Cash Flow Statement 116 line items

Line Item	Tag	Value	Unit	Period
Net loss	`NetIncomeLoss`	$-2.38M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-970.00K	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-2.09M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-3.69M	USD	2 Qtrs
Depreciation	`Depreciation`	$27.00K	USD	2 Qtrs
Depreciation	`Depreciation`	$16.00K	USD	1 Quarter
Depreciation	`Depreciation`	$39.00K	USD	2 Qtrs
Depreciation	`Depreciation`	$22.00K	USD	1 Quarter
Other non-cash items	`OtherNoncashIncomeExpense`	$56.00K	USD	1 Quarter
Other non-cash items	`OtherNoncashIncomeExpense`	$-14.00K	USD	2 Qtrs
Other non-cash items	`OtherNoncashIncomeExpense`	$25.00K	USD	1 Quarter
Other non-cash items	`OtherNoncashIncomeExpense`	$56.00K	USD	2 Qtrs
Share based compensation	`ShareBasedCompensation`	$635.00K	USD	2 Qtrs
Share based compensation	`ShareBasedCompensation`	$837.00K	USD	2 Qtrs
Share based compensation	`ShareBasedCompensation`	$556.00K	USD	1 Quarter
Share based compensation	`ShareBasedCompensation`	$155.00K	USD	1 Quarter
Loss (Profit) from exchange differences on cash and cash equivalents	`ForeignCurrencyTransactionGainLossBeforeTax`	$16.00K	USD	1 Quarter
Loss (Profit) from exchange differences on cash and cash equivalents	`ForeignCurrencyTransactionGainLossBeforeTax`	$-12.00K	USD	1 Quarter
Loss (Profit) from exchange differences on cash and cash equivalents	`ForeignCurrencyTransactionGainLossBeforeTax`	$4.00K	USD	2 Qtrs
Loss (Profit) from exchange differences on cash and cash equivalents	`ForeignCurrencyTransactionGainLossBeforeTax`	$84.00K	USD	2 Qtrs
Accounts receivables	`IncreaseDecreaseInAccountsReceivable`	$14.00K	USD	1 Quarter
Accounts receivables	`IncreaseDecreaseInAccountsReceivable`	$43.00K	USD	2 Qtrs
Accounts receivables	`IncreaseDecreaseInAccountsReceivable`	$49.00K	USD	1 Quarter
Accounts receivables	`IncreaseDecreaseInAccountsReceivable`	$4.00K	USD	2 Qtrs
Inventory	`IncreaseDecreaseInInventories`	$302.00K	USD	2 Qtrs
Inventory	`IncreaseDecreaseInInventories`	$-99.00K	USD	2 Qtrs
Inventory	`IncreaseDecreaseInInventories`	$177.00K	USD	1 Quarter
Inventory	`IncreaseDecreaseInInventories`	$-200.00K	USD	1 Quarter
Medigus	`IncreaseDecreaseInDueFromRelatedPartiesCurrent`	$111.00K	USD	2 Qtrs
Medigus	`IncreaseDecreaseInDueFromRelatedPartiesCurrent`	$95.00K	USD	1 Quarter
Medigus	`IncreaseDecreaseInDueFromRelatedPartiesCurrent`	$-60.00K	USD	2 Qtrs
Medigus	`IncreaseDecreaseInDueFromRelatedPartiesCurrent`	$-14.00K	USD	1 Quarter
Other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$254.00K	USD	2 Qtrs
Other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$509.00K	USD	2 Qtrs
Other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$404.00K	USD	1 Quarter
Other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$201.00K	USD	1 Quarter
Accounts payables	`IncreaseDecreaseInAccountsPayable`	$-189.00K	USD	1 Quarter
Accounts payables	`IncreaseDecreaseInAccountsPayable`	$224.00K	USD	2 Qtrs
Accounts payables	`IncreaseDecreaseInAccountsPayable`	$128.00K	USD	1 Quarter
Accounts payables	`IncreaseDecreaseInAccountsPayable`	$133.00K	USD	2 Qtrs
Contract fulfilment assets	`IncreaseDecreaseInContractWithCustomerLiability`	-	USD	2 Qtrs
Contract fulfilment assets	`IncreaseDecreaseInContractWithCustomerLiability`	-	USD	1 Quarter
Contract fulfilment assets	`IncreaseDecreaseInContractWithCustomerLiability`	$-380.00K	USD	2 Qtrs
Contract fulfilment assets	`IncreaseDecreaseInContractWithCustomerLiability`	$-140.00K	USD	1 Quarter
Contract liabilities	`IncreaseDecreaseInOtherEmployeeRelatedLiabilities`	$170.00K	USD	2 Qtrs
Contract liabilities	`IncreaseDecreaseInOtherEmployeeRelatedLiabilities`	$-126.00K	USD	1 Quarter
Contract liabilities	`IncreaseDecreaseInOtherEmployeeRelatedLiabilities`	$126.00K	USD	1 Quarter
Contract liabilities	`IncreaseDecreaseInOtherEmployeeRelatedLiabilities`	$537.00K	USD	2 Qtrs
Accrued compensation expenses	`IncreaseDecreaseInWorkersCompensationLiabilities`	$140.00K	USD	1 Quarter
Accrued compensation expenses	`IncreaseDecreaseInWorkersCompensationLiabilities`	$60.00K	USD	2 Qtrs
Accrued compensation expenses	`IncreaseDecreaseInWorkersCompensationLiabilities`	$36.00K	USD	2 Qtrs
Accrued compensation expenses	`IncreaseDecreaseInWorkersCompensationLiabilities`	$60.00K	USD	1 Quarter
Other accrued expenses	`IncreaseDecreaseInOtherAccruedLiabilities`	$-144.00K	USD	1 Quarter
Other accrued expenses	`IncreaseDecreaseInOtherAccruedLiabilities`	$-22.00K	USD	2 Qtrs
Other accrued expenses	`IncreaseDecreaseInOtherAccruedLiabilities`	$-155.00K	USD	1 Quarter
Other accrued expenses	`IncreaseDecreaseInOtherAccruedLiabilities`	$-356.00K	USD	2 Qtrs
Net cash flows used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-2.28M	USD	2 Qtrs
Net cash flows used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-1.14M	USD	1 Quarter
Net cash flows used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-3.05M	USD	2 Qtrs
Net cash flows used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-2.28M	USD	1 Quarter
Purchase of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$36.00K	USD	1 Quarter
Purchase of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$221.00K	USD	2 Qtrs
Purchase of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$53.00K	USD	1 Quarter
Purchase of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$170.00K	USD	2 Qtrs
Net cash flows used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-221.00K	USD	2 Qtrs
Net cash flows used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-170.00K	USD	2 Qtrs
Net cash flows used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-36.00K	USD	1 Quarter
Net cash flows used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-53.00K	USD	1 Quarter
Loan repayment to Medigus	`RepaymentsOfRelatedPartyDebt`	-	USD	2 Qtrs
Loan repayment to Medigus	`RepaymentsOfRelatedPartyDebt`	$81.00K	USD	2 Qtrs
Loan repayment to Medigus	`RepaymentsOfRelatedPartyDebt`	-	USD	1 Quarter
Loan repayment to Medigus	`RepaymentsOfRelatedPartyDebt`	-	USD	1 Quarter
Proceeds from exercise of warrants	`ProceedsFromWarrantExercises`	$2.50M	USD	2 Qtrs
Proceeds from exercise of warrants	`ProceedsFromWarrantExercises`	-	USD	2 Qtrs
Proceeds from exercise of warrants	`ProceedsFromWarrantExercises`	-	USD	1 Quarter
Proceeds from exercise of warrants	`ProceedsFromWarrantExercises`	$1.72M	USD	1 Quarter
Proceeds from issuance of shares and warrants	`ProceedsFromIssuanceOfSharesAndWarrants`	$19.12M	USD	2 Qtrs
Proceeds from issuance of shares and warrants	`ProceedsFromIssuanceOfSharesAndWarrants`	$1.95M	USD	1 Quarter
Proceeds from issuance of shares and warrants	`ProceedsFromIssuanceOfSharesAndWarrants`	$9.62M	USD	1 Quarter
Proceeds from issuance of shares and warrants	`ProceedsFromIssuanceOfSharesAndWarrants`	$2.86M	USD	2 Qtrs
Net cash flows provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$21.62M	USD	2 Qtrs
Net cash flows provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$11.34M	USD	1 Quarter
Net cash flows provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$1.95M	USD	1 Quarter
Net cash flows provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$2.78M	USD	2 Qtrs
PROFIT (LOSS) FROM EXCHANGE DIFFERENCES ON CASH AND CASH EQUIVALENTS	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$84.00K	USD	2 Qtrs
PROFIT (LOSS) FROM EXCHANGE DIFFERENCES ON CASH AND CASH EQUIVALENTS	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$4.00K	USD	2 Qtrs
PROFIT (LOSS) FROM EXCHANGE DIFFERENCES ON CASH AND CASH EQUIVALENTS	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$-12.00K	USD	1 Quarter
PROFIT (LOSS) FROM EXCHANGE DIFFERENCES ON CASH AND CASH EQUIVALENTS	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$16.00K	USD	1 Quarter
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$761.00K	USD	1 Quarter
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$18.40M	USD	2 Qtrs
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$9.02M	USD	1 Quarter
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$363.00K	USD	2 Qtrs
BALANCE OF CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE PERIOD	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$21.77M	USD	Point-in-time
BALANCE OF CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE PERIOD	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$12.75M	USD	Point-in-time
BALANCE OF CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE PERIOD	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$3.61M	USD	Point-in-time
BALANCE OF CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE PERIOD	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$3.37M	USD	Point-in-time
BALANCE OF CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE PERIOD	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$3.25M	USD	Point-in-time
BALANCE OF CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE PERIOD	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$2.85M	USD	Point-in-time
BALANCE OF CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$21.77M	USD	Point-in-time
BALANCE OF CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$12.75M	USD	Point-in-time
BALANCE OF CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$3.61M	USD	Point-in-time
BALANCE OF CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$3.37M	USD	Point-in-time
BALANCE OF CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$3.25M	USD	Point-in-time
BALANCE OF CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$2.85M	USD	Point-in-time
Medigus loan settled against Medigus receivable	`LoanFromParentCompanySettledAgainstReceivableFromParentCompany`	-	USD	1 Quarter
Medigus loan settled against Medigus receivable	`LoanFromParentCompanySettledAgainstReceivableFromParentCompany`	$41.00K	USD	2 Qtrs
Medigus loan settled against Medigus receivable	`LoanFromParentCompanySettledAgainstReceivableFromParentCompany`	-	USD	2 Qtrs
Medigus loan settled against Medigus receivable	`LoanFromParentCompanySettledAgainstReceivableFromParentCompany`	-	USD	1 Quarter
Conversion of a loan from Medigus	`ConversionOfLoanFromParentCompany`	-	USD	2 Qtrs
Conversion of a loan from Medigus	`ConversionOfLoanFromParentCompany`	$381.00K	USD	1 Quarter
Conversion of a loan from Medigus	`ConversionOfLoanFromParentCompany`	-	USD	1 Quarter
Conversion of a loan from Medigus	`ConversionOfLoanFromParentCompany`	$381.00K	USD	2 Qtrs
Issuance expenses	`IssuanceExpenses`	-	USD	1 Quarter
Issuance expenses	`IssuanceExpenses`	-	USD	2 Qtrs
Issuance expenses	`IssuanceExpenses`	$45.00K	USD	1 Quarter
Issuance expenses	`IssuanceExpenses`	$45.00K	USD	2 Qtrs

Stockholders Equity 27 line items

Line Item	Tag	Value	Unit	Period
Beginning balance, value	`StockholdersEquity`	$4.25M	USD	Point-in-time
Beginning balance, value	`StockholdersEquity`	$3.96M	USD	Point-in-time
Beginning balance, value	`StockholdersEquity`	$2.72M	USD	Point-in-time
Beginning balance, value	`StockholdersEquity`	$22.34M	USD	Point-in-time
Beginning balance, value	`StockholdersEquity`	$22.48M	USD	Point-in-time
Beginning balance, value	`StockholdersEquity`	$2.52M	USD	Point-in-time
Issuance of shares and warrants	`StockIssuedDuringPeriodValueOfSharesAndWarrants`	$1.95M	USD	1 Quarter
Issuance of shares and warrants	`StockIssuedDuringPeriodValueOfSharesAndWarrants`	$2.86M	USD	2 Qtrs
Issuance of shares and warrants	`StockIssuedDuringPeriodValueOfSharesAndWarrants`	$19.12M	USD	2 Qtrs
Stock based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$170.00K	USD	1 Quarter
Stock based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$871.00K	USD	2 Qtrs
Stock based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$556.00K	USD	1 Quarter
Stock based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$635.00K	USD	2 Qtrs
Exercise of warrants	`ExerciseOfWarrants`	$1.68M	USD	1 Quarter
Exercise of warrants	`ExerciseOfWarrants`	$2.46M	USD	2 Qtrs
Conversion of a loan from Medigus	`StockIssuedDuringPeriodVlaueConversionOfLoanFromParentCompany`	$381.00K	USD	2 Qtrs
Conversion of a loan from Medigus	`StockIssuedDuringPeriodVlaueConversionOfLoanFromParentCompany`	$381.00K	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-2.38M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-970.00K	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-2.09M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-3.69M	USD	2 Qtrs
Ending balance, value	`StockholdersEquity`	$4.25M	USD	Point-in-time
Ending balance, value	`StockholdersEquity`	$3.96M	USD	Point-in-time
Ending balance, value	`StockholdersEquity`	$2.72M	USD	Point-in-time
Ending balance, value	`StockholdersEquity`	$22.34M	USD	Point-in-time
Ending balance, value	`StockholdersEquity`	$22.48M	USD	Point-in-time
Ending balance, value	`StockholdersEquity`	$2.52M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.